Sensorion has reported positive topline results from the SENS-111-202 study after the trial met its primary endpoint of tolerability.

The SENS-111-202 study is designed to evaluate the safety and pharmacodynamic effects of Seliforant (SENS-111) for the treatment of experimentally evoked vestibular imbalance.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As part of the randomised, double-blind, placebo-controlled and Meclizine-calibrated crossover trial, Sensorion randomised 32 subjects to receive a dose of each of the four-treatment regimens, with a week between every treatment.

The treatments were Seliforant 100mg, Seliforant 200mg, Meclizine 50mg and a placebo.

The trial was carried out in the Netherlands, with repeated objective psychometric measures of vigilance and cognitive performance being the primary objectives.

“This significant achievement in the development of Seliforant adds to the evidence that Seliforant has the potential to become a new key drug in the treatment of acute vertigo.”

The new topline results showed that Seliforant did not affect vigilance and cognitive performance during a motion stimulus.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study showed that compared with Meclizine, Seliforant did not have any negative central nervous system (CNS) side effects including sedation, impairment of memory and cognitive performance.

Meclizine is a type of histamine H1 receptor antagonist, which is used as the first line of treatment in acute vertigo and motion sickness in the US. The drug has a sedative effect that stops the patient from functioning during treatment of the vertigo attack.

Sensorion CEO Nawal Ouzren said: “This significant achievement in the development of Seliforant adds to the evidence that Seliforant has the potential to become a new key drug in the treatment of acute vertigo with a robust safety profile compared to current standard of care.

“The next milestone is the Phase ll proof of concept (POC) efficacy trial readout in AUV in H2 2019.”

Sensorion’s Seliforant is an investigational histamine type 4 receptor antagonist class that aims to target the symptomatic treatment of vertigo crises.